Breaking News

Transgenomic, Raptor Enter Genetic Testing Services Pact

April 4, 2014

Will provide testing services for Raptor’s trial in Leigh syndrome

Transgenomic, Inc. has entered an agreement with Raptor Pharmaceuticals, Inc. to provide genetic testing services for Raptor’s clinical trial evaluating RP103 as a potential treatment for Leigh syndrome and other inherited mitochondrial disorders. Leigh syndrome is a severe neurological disorder characterized by progressive loss of mental and movement abilities and typically results in death within a few years, usually due to respiratory failure.
 
“We look forward to working with Raptor and the study investigators, using our leading-edge mitochondrial genetic testing capabilities to uncover the important genetic profiling information required for the successful execution of this clinical trial,” said Paul Kinnon, president and chief executive officer of Transgenomic. “This is a key example of how Transgenomic works with pharmaceutical companies to employ complementary genetic tests designed to improve clinical diagnoses and outcomes.”
blog comments powered by Disqus
  • CMC Biologics: Growing Through Innovation

    Tim Wright, Editor||January 28, 2016
    The new chief exec talks about industry trends and growth plans.

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements